文献速递妇科

吉西他滨治疗复发性卵巢癌的系统综述与荟萃分析

Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.
PubMed 文献 · Gynecol Oncol · 2019-10-08

该系统综述与荟萃分析纳入6项随机对照试验,评估吉西他滨单药或联合方案治疗复发性卵巢癌。在铂耐药患者中,吉西他滨与聚乙二醇脂质体多柔比星的总生存和无进展生存差异无统计学意义,吉西他滨组中性粒细胞减少显著更多,脂质体多柔比星组手足综合征显著更多。吉西他滨联合卡铂较卡铂单药无进展生存更长(HR 0.72,95%CI 0.58-0.9),联合贝伐珠单抗较无贝伐珠单抗无进展生存显著更优(HR 0.48,95%CI 0.39-0.61)。

要点

  • 铂耐药复发性卵巢癌中,吉西他滨与聚乙二醇脂质体多柔比星的总生存和无进展生存差异无统计学意义。
  • 吉西他滨组中性粒细胞减少显著更多,聚乙二醇脂质体多柔比星组手足综合征显著更多。
  • 吉西他滨联合卡铂较卡铂单药无进展生存更长(HR 0.72,95%CI 0.58-0.9),总生存差异无统计学意义。

核心结论

  • 结果表明吉西他滨是治疗铂敏感和铂耐药复发性卵巢癌的有效且安全的药物,但可能突出需要在重度预处理患者中开展新的随机研究。

研究设计与样本

  • 系统综述与荟萃分析,纳入所有研究吉西他滨治疗复发性卵巢癌并报告总生存、无进展生存和毒性数据的随机对照试验。
  • 检索CENTRAL、EMBASE和MEDLINE,检索日期为2019年5月31日。
  • 共纳入6项随机对照试验,评估吉西他滨单药或联合治疗。

主要发现

  • 两项研究在铂耐药复发性卵巢癌女性中比较吉西他滨与聚乙二醇脂质体多柔比星,总生存和无进展生存差异无统计学意义。
  • 吉西他滨治疗与显著更多的中性粒细胞减少相关,而聚乙二醇脂质体多柔比星与显著更多的手足综合征相关。
  • 一项研究评估卡铂联合吉西他滨对比卡铂,总生存差异无统计学意义,但吉西他滨联合卡铂的无进展生存更长(HR 0.72,95%CI 0.58-0.9)。
  • 一项研究评估吉西他滨对比吉西他滨联合帕妥珠单抗,两组总生存和无进展生存相似。
  • 一项研究比较吉西他滨联合卡铂对比吉西他滨、卡铂联合贝伐珠单抗,两组总生存相似,贝伐珠单抗组无进展生存显著更优(HR 0.48,95%CI 0.39-0.61)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: More than 80 % of women with advanced ovarian cancer relapse either during or after adjuvant therapy. Platinum-sensitive women are rechallenged with a platinum-combination therapy and platinum-resistant women are challenged with non-platinum drugs. Gemcitabine is one of many treatments that can be used both as single-agent or as combination therapy for the treatment of recurrent ovarian cancer. METHODS: We included all randomised controlled trials investigating patients treated with gemcitabine for recurrent ovarian cancer and reporting data on overall survival, progression-free survival and toxicity. CENTRAL, EMBASE and MEDLINE were searched on the 31st of May 2019. RESULTS: We included six randomised controlled trials that evaluated gemcitabine either alone or as combination therapy. Two studies compared gemcitabine to pegylated liposomal doxorubicin in women with platinum-resistant recurrent ovarian cancer. Difference in overall and progression-free survival was non-significant. Gemcitabine treatment was associated with significantly more neutropenia, whereas pegylated liposomal doxorubicin was associated with significantly more hand-foot syndrome. One study evaluated carboplatin and gemcitabine to carboplatin. Difference in overall survival was non-significant, but progression-free survival was longer with gemcitabine and carboplatin (HR: 0.72, 95% CI 0.58-0.9). One study evaluated gemcitabine with gemcitabine and pertuzumab. Overall survival and progression-free survival was similar between the two arms. One study compared gemcitabine and carboplatin to gemcitabine, carboplatin and bevacizumab. Overall survival was similar in the two arms. Progression-free survival was significantly better in the bevacizumab arm (HR 0.48 95% CI 0.39-0.61). One study compared etoposide and gemcitabine to etoposide. The study showed similar overall survival and progression-free survival. DISCUSSION: The results show that gemcitabine is an active and safe agent in the treatment of both platinum-sensitive and resistant recurrent ovarian cancer but might highlight the need of new randomised studies in heavily pre-treated patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Berg T, Nøttrup TJ, Roed H, et al. Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis. Gynecol Oncol. 2019. PMID: 31604664. doi:10.1016/j.ygyno.2019.09.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。